$ACHN Headlines Six stocks to watch 1:47 p.m. Aug. 27,

New Post Public Reply Private Reply Replies (0) Message Board

Aug 31, 2014 at 10:49 AM

$ACHN Headlines

Six stocks to watch 1:47 p.m. Aug. 27, 2014 - The Trading Deck
S&P 500 reaches firmer technical ground 11:30 a.m. Aug. 18, 2014 - Michael Ashbaugh
Stocks trim Ukraine-inspired fall, post weekly gain 4:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy

4 Biotechs That Might Be Bought Soon 10:53 a.m. Aug. 29, 2014 - Investors Business Daily
Market Posts Best August In 14 Years. Why Don't Investors Feel Better? 10:30 a.m. Aug. 29, 2014 - Seeking Alpha
InsiderInsights.com Daily Round Up 8/27/14: Southern Copper, Republic Services, CIBER, Penn Virginia 10:05 a.m. Aug. 28, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – LCI ISIS CNC ACHN 8:00 a.m. Aug. 28, 2014 - InvestorPlace.com
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog 10:32 a.m. Aug. 27, 2014 - Zacks.com
Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape 8:37 a.m. Aug. 27, 2014 - Zacks.com
Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets 12:37 p.m. Aug. 26, 2014 - benzinga.com
3 Biotechs Surging Following InterMune Takeover - Analyst Blog 11:07 a.m. Aug. 26, 2014 - Zacks.com
Morning Market Movers 8:38 a.m. Aug. 26, 2014 - benzinga.com
Benzinga's Top #PreMarket Gainers 7:11 a.m. Aug. 26, 2014 - benzinga.com
Biggest Movers in Healthcare Stocks Now – ISIS THRX EXAS CBPO 6:00 a.m. Aug. 26, 2014 - InvestorPlace.com
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog 6:25 p.m. Aug. 25, 2014 - Zacks.com
More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News 4:43 p.m. Aug. 25, 2014 - Zacks.com
Achillion Shares Spike Higher, Near $11 As UBS Analyst Sees Possibility Of M&A 2:04 p.m. Aug. 25, 2014 - benzinga.com
Biggest Movers in Healthcare Stocks Now – ACHN IRWD PCRX CBST 1:45 p.m. Aug. 25, 2014 - InvestorPlace.com
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels ... 1:25 a.m. Aug. 25, 2014 - GuruFocus.com
Benzinga's Top #PreMarket Losers 7:23 a.m. Aug. 22, 2014 - benzinga.com
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog 5:00 p.m. Aug. 21, 2014 - Zacks.com
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog 4:27 p.m. Aug. 20, 2014 - Zacks.com
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog 11:08 a.m. Aug. 20, 2014 - Zacks.com

Critical Alerts For Achillion Pharmaceuticals, Intel, YY, JA Solar and Skullcandy Released By InvestorsObserver 9:31 a.m. Aug. 26, 2014 - PR Newswire - PRF
Biotechnology Stocks to Keep an Eye On 9:02 a.m. Aug. 20, 2014 - ACCESSWIRE
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo 8:40 a.m. Aug. 20, 2014 - PR Newswire - PRF
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors 4:06 p.m. Aug. 19, 2014 - GlobeNewswire
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"

7:00 a.m. Aug. 15, 2014 - GlobeNewswire
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 4:06 p.m. Aug. 7, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Synergy Resources, Invensense, JinkoSolar, and Harley-Davidson Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion 5:50 a.m. July 7, 2014 - PR Newswire - PRF
Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes 4:06 p.m. July 1, 2014 - GlobeNewswire
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AAR's Agreement with Airbus Elevates Repair Capabilities

A Strategic Play in the Aviation Game Alright, if you've been scanning the skies of the aviation aftermarket lately, AAR's recent maneuver ought to catch your eye. These folks have clinched a multi-year deal with Airbus Avionics, paving the runway for expanded radome repair capabilities. For those less acquainted with the inner workings of aviation, radomes protect those...

Cohen & Steers Sees Steady Rise in October AUM

Market Pushes Cohen & Steers Forward It's been a wild ride for financial managers lately, and Cohen & Steers, Inc. (NYSE: CNS) isn't exempt from the rollercoaster. As of October 31, 2026, they've reported assets under management (AUM) climbing to $99.6 billion—thanks to a hefty market appreciation of $4 billion. Not too shabby when you're dealing with the...

AppLovin Faces Fraud Lawsuit, Investors Alerted

AppLovin's Lawsuit: A Wake-Up Call for Investors The market never forgets, even if some investors might wish reality wasn’t so harsh. On the chopping block this time is AppLovin Corporation (NASDAQ: APP). Seems like their fairy tale with AI turned into a courtroom drama, one that’s throwing a real curveball on those rosy earnings expectations. What's the Case All...

Foundayo Aims to Revolutionize Sleep Apnea Treatment

Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...

Pak Mail Expands: Franchisee Adds Location Fast

Franchise Growth: Adding Another Brick When's the last time you heard of a franchisee eager enough to nab a second location? Well, that's exactly what's happening with Manny Zussman, who’s decided his Boulder Pak Mail outlet wasn’t keeping him busy enough. This entrepreneurial spirit's on full display as he's launching another Pak Mail over in Westminster, Colorado....

AssureTrace Brings Graham Clark on Board for Growth

Serialization's Fresh Outlook So, here we are—with one sharp mover joining the pack. Graham Clark is stepping into AssureTrace as the Chief Revenue Officer and Business Director. Another suit hopping on yet another board, but this time, it's got some seasoning we're looking at. Clark's packing over 23 years of serialization hustle, and that's not small change in the...

Upsher-Smith Rolls Out New Eye Solutions, Impacts Market

Upsher-Smith's Bold Move in Ophthalmics Right out of Maple Grove, Minnesota, Upsher-Smith Laboratories is shaking up the eye care scene with the launch of two strengths of Brimonidine Tartrate Ophthalmic Solution. We're talking 0.1% and 0.15%, folks. This ain't just a dribble in the ocean—these products are sailing into a $115 million market arena, according to IQVIA....

Navigating Simultaneous Home Buy and Sell Strategies

Juggling Two Housing Transactions You ever tried juggling chainsaws? That's what buying and selling your home at the same time can feel like. Selling First: Playing It Safe Some folks swear by selling their current home first, and there's good reason. It locks in your financial windfall, giving you a clear picture of your down payment and affordability. No more guessing...

Rainmaker's Cloud Seeding Milestone: Big Leap or Hype?

Pioneering Cloud Seeding: Rainmaker's Big Talk Mornings like this, I find myself wondering if we're still all buying snake oil—or if the future just landed in our laps. Rainmaker Technology Corporation just dropped what might be a game-changer or a grand illusion for those of us with a finger on the pulse of water tech. Their study in 'Atmosphere' paints a picture of...

Palmdale Expands Reach with Tri-County Acquisition

Fueling Up a New Chapter in Florida Once in a blue moon, you see a move that just clicks—and Palmdale Oil snapping up Tri-County Oil Distributors is that kind of slick deal. We're not talking about some Wall Street high-flyer here—this is down-to-earth business in North Central Florida, where local ties and trust still mean something. Why Tri-County Fits the Bill If...